Evidence map›Paper›PMID 32643520›Full record

ArticleHuman vaccines & immunotherapeutics2021

Seroprevalence survey for Varicella among healthcare workers and medical students in Italy.

Ottavia Balbi, Savino Baldi, Stefano Rizza, Antonio Pietroiusti, Stefano Perrone, Luca Coppeta

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06901362 (Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06901362 completednot on this mapstarted 2025, after this paper: background citation

Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program

TypeobservationalSponsorThammasat UniversityRan2025 to 2025Enrolled401ConditionsHealthy, Healthy Adult
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ottavia BalbiDepartment of Biomedicine and Prevention, University of Rome, Tor Vergata , Italy.
Savino BaldiDepartment of Biomedicine and Prevention, University of Rome, Tor Vergata , Italy.ORCID 0000-0003-0823-1420
Stefano RizzaDepartment of Systems Medicine, University of Rome Tor Vergata , Rome, Italy.
Antonio PietroiustiDepartment of Biomedicine and Prevention, University of Rome, Tor Vergata , Italy.
Stefano PerroneDepartment of Biomedicine and Prevention, University of Rome, Tor Vergata , Italy.
Luca CoppetaDepartment of Biomedicine and Prevention, University of Rome, Tor Vergata , Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Varicella is a potentially serious infectious disease caused by Varicella-Zoster Virus (VZV). In Italy childhood varicella vaccine have gradually introduced into national immunization program since 2003 and from 2017 a two-doses schedule has been stated nationally for all newborns and has become compulsory for school attendance. VZV exposures among healthcare workers (HCWs) and patients can be really dangerous and expensive. According to Centers of Disease Control and Italian national immunization plan health care, institutions should verify that all HCWs have clear evidence of immunity to VZV and should ensure that susceptible subjects will receive 2 doses of VZV vaccine. Currently, the vaccination of HCWs is not compulsory in Italy and the risk of varicella infection among these subjects is not well known. We evaluated the clinical records of 840 HCWs (256 male and 584 female) who underwent the annual occupational screening, from 1st January to 31st August 2018. HCWs were divided into three subgroups according to their age: 18-30, 31-40, and over 40 years old. We compared the mean values of IgG-specific antibodies between the age group through analysis of variance (ANOVA). A total of 784 (93.33%) HCWs were protected for VZV IgG antibodies level. There wasn't a significant difference between male and female while was found between age group (

Indexed as

ChickenpoxStudents, MedicalAdolescentAdultAntibodies, ViralChickenpox VaccineChildFemaleHealth PersonnelHerpesvirus 3, HumanHumansInfant, NewbornItalyMaleSeroepidemiologic StudiesVaccinationAntibodies, ViralChickenpox Vaccinehealthcare workersinfectionOccupational epidemiologyvaricellavaricella vaccination

Identifiers

PMID32643520
PMCPMC7899655
OpenAlexW3041356662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.